



Add a dose of Reliance Pharma Fund to your portfolio!

An open ended equity scheme investing in pharma sector

Pharma Sector at reasonable current valuations.


Participation across sub-themes like domestic, international, healthcare services etc

Well diversified multicap portfolio

Contact your financial advisor for further details
Call 1860 266 0111* | www.reliancemutual.com

This product is suitable for investors who are seeking*

- Long term capital growth.
- Investment in equity and equity related Securities of pharma & other associated companies
- *Investors should consult their financial advisors if in doubt about whether the product is suitable for them.



Investors understand that their principal will be at High risk

*Local call charges apply.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Reliance Pharma Fund

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Inception Date	5th June 2004
Fund Manager	Sailesh Raj Bhan
Benchmark	S&P BSE Healthcare TRI
Month end AUM as on 31.07.2019	Rs. 2,344.17 crs

Current Investment Philosophy

- ▶ The fund is a combination of large cap and mid cap companies with an aim to provide consistent returns.
- ▶ Investments are spread across all the important segments of the industry - Domestic & International, Branded & Generics, CRAMS (Contract Research & Manufacturing) and Healthcare Services – Insurance, Hospitals, Diagnostics.
- ▶ Relative value within the important sub segments of the market is an important investment parameter.
- ▶ Low capital intensive sector that is less impacted by market volatility with good growth visibility and decent cash flows.
- ▶ The recommended investment horizon is around 2-3 yrs.
- ▶ Given the reasonable current valuations and estimated earnings growth, the sector is likely to benefit from change in investor sentiment in its favor.

Asset Allocation: As on 31st July 2019

Equities	98.82%
Cash and Other Receivables	1.18%

Investment Style: As on 31st July 2019

Value	Blend	Growth	
			Large
			Mid
			Small

Key Portfolio Attributes: As on 31st July 2019

Sharpe Ratio⁵	-0.11
Portfolio Turnover (Times)	0.35

SNote: The above measures have been calculated using monthly rolling returns for 36 months period with 5.75% risk free return (FBIL Overnight MIBOR as on 31/07/2019).

Top 10 Stock Holdings: As on 31st July 2019

Stocks	Allocation (%)
Sun Pharmaceutical Industries Limited	11.83
Divi's Laboratories Limited	10.45
Cipla Limited	9.56
Aurobindo Pharma Limited	8.04
Lupin Limited	7.50
Dr. Reddy's Laboratories Limited	6.59
Syngene International Limited	6.46
Abbott India Limited	6.26
Sanofi India Limited	5.90
Fortis Healthcare Limited	5.84

Note: For complete portfolio, please refer website www.reliancecmutual.com. Current Portfolio Allocation is based on the prevailing market conditions and is subject to changes depending on the fund manager's view of the equity markets. Sector(s) / Stock(s) / Issuer(s) mentioned above are for the purpose of disclosure of the portfolio of the Scheme(s) and should not be construed as recommendation.

Sector Update & Outlook

Indian Pharma Sector is one of the most globally competitive sectors out of India, having material market share in the US and selling products to over 100 countries in addition to meeting the requirements of a huge domestic market. We believe Indian Pharma sector is primed for a meaningful recovery due to:

- ▶ **Start of New Earning Cycle:** Earnings, which was the biggest challenge for the last 3 years, is starting to improve across segments due to low base, efficiency, currency benefits, etc.
- ▶ **Domestic Business Opportunity:** India specific businesses are expected to grow at a faster rate as price reductions & policy interventions are factored in current prices. This coupled with huge under penetration, rising income etc. present a multi-year growth opportunity.
- ▶ **Focus on Healthcare:** Focus on Healthcare through schemes like 'Ayushman Bharat' or National Health Protection Scheme which would cover millions of families, will benefit Healthcare services like Hospitals, Diagnostics etc.
- ▶ **US Generics revival:** Excessive pricing pressure is bottoming out, rise in FDA plant resolutions and product approvals are likely to lead a recovery in US business.

Common Source: MFI, Bloomberg, RMF Internal Research

Risk factor & Disclaimer: Trading volumes and settlement periods may restrict liquidity in equity and debt investments. Investment in Debt is subject to price, credit, and interest rate risk. The NAV of the Scheme may be affected, inter alia, by changes in the market conditions, interest rates, trading volumes, settlement periods and transfer procedures. The NAV may also be subjected to risk associated with investment in derivatives, foreign securities or script lending as may be permissible by the Scheme Information Document. For further details, please refer Scheme Information Document (SID).

The Scheme has undergone fundamental attribute change w.e.f. April 28, 2018. Kindly refer notice cum addendum no. 200 dated March 23, 2018 available on website (www.reliancecmutual.com) for the details of the aforementioned change before making investment decision. The views being expressed only constitute opinions and therefore cannot be considered as guidelines, recommendations or as a professional guide for the readers. Before making any investments, the readers are advised to seek independent professional advice, verify the contents in order to arrive at an informed investment decision. None of the Sponsor, the Investment Manager, the Trustee, their respective directors, employees, affiliates or representatives shall be liable in any way for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including on account of lost profits arising from the information contained in this material.

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.